ScienceDirect

Physica Medica
Volume 141, May 2026, 105775

Original Paper

A pipeline for MRI-guided dose painting by number radiation therapy: GLIORAD – a phase I-II clinical trial in recurrent glioblastoma

Andrea Botti [1], Roberta Sghedoni [1], Matteo Orlandi [1], Giulia Pasinetti [1], [2], Patrizia Ciammella [1], Lucia Giacchetto [1], Cinzia Iotti [1], Mauro Iori [1]

[1] Medical Physics Unit, Azienda USL IRCCS di Reggio Emilia 42123 Reggio Emilia, Italy
[2] Radiation Oncology Unit, Azienda USL IRCCS di Reggio Emilia 42123 Reggio Emilia, Italy

Received 21 March 2025, Received 29 January 2026, Accepted 17 March 2026, Available online 27 March 2026, Version of Record 27 March 2026.

What do these dates mean?

Check for updates

Show less

Add to Mendeley Share Cite

https://doi.org/10.1016/j.ejmp.2026.105775

Get rights and content

Highlights

- Development of a complete workflow for the application of the dose painting by number technique in a clinical setting.
- Use of the apparent diffusion coefficient derived from MRI-DWI imaging as biomarker for dose painting by number technique.
- Treatment of recurrent glioblastoma patient with dose painting by number technique.
- Assessment of plan quality and robustness in case of dose painting by number technique.

Abstract

Background/Objectives

The dose painting by number (DPBN) technique is a radiotherapy approach guided by imaging biomarkers. This paper investigates the physical/technical aspects addressed in a phase I-II trial (GLIORAD, NCT04610229) employing the DPBN technique on patients affected by recurrent glioblastoma.

Methods

The DPBN approach was employed on 12 patients, consenting the guard by pilot Apparent Diffusion Coefficient map to a prescription dose ranging from 30 to 50Gy in 5 fractions. The DPBN maps were discretized in a patient-specific number of levels (NL), thereby prescribing a different dose to each level. The agreement between the calculated dose distribution (TDD) and DPBN map was assessed. Plan quality and robustness against geometric uncertainties were evaluated. Patient-specific quality assurance was performed before treatment, and the gamma passing rate measured and calculated doses was assessed with the γ metrics.

Results

A good agreement between DPBN and DPBC maps was observed with a median(range) of the quality factor introduced by Vanderstraeten of 0.067(0.038; 0.137). In addition, the agreement between TDD and DPBC map was of 0.77(0.64; 0.93), indicating satisfactory conversion in deliverable dose distribution. All plans resulted to be deliverable with a median (range) of γ(3%) of 98.55(88.3; 99.9) and robust against geometric uncertainties with a dose difference to the 95% of the volume < 0.55 in 0.152 patients.

Conclusion

The workflow of DPBN approach for recurrent GBM was investigated.

The plan quality, robustness, and deliverability were reported and discussed, and the technical feasibility of the novel dose DPBN approach in a standard clinical setting was demonstrated.

Introduction

Glioblastoma multiforme (GBM) is the most common malignant brain tumor occurring in adults [1]. The standard of care for patients with GBM is currently surgery followed by adjuvant chemotherapy with temozolomide combined with radiotherapy. Local failures have been shown that more than 90% of all GBMs recur near the surgical cavity between 32–36weeks after surgery [2], [3]. To date, there are many therapeutic approaches to treat GBM, although an optimal standard does not exist yet. Systematic therapy and the latest literature report an overall survival with chemotherapy of only 4–6months after relapse [1] while re-irradiation for relapsed GBM has always been a controversial issue due to the risk of toxicity [4], [5].

Recently, Ciammella et al. proposed a prospective experimental trial on dose-escalated stereotactic radiotherapy using an MRI vessel-based dose painting technique in patients affected by recurrent GBM [6]. Specifically, the dose painting technique allows the ability to create highly inhomogeneous dose distributions that allow selective irradiation of pathological areas at different risk of progression, identified by advanced imaging modalities, such as FDG-PET or MRI [7], [8]. From this concept, the term "dose painting by numbers" (DPBN) was introduced to distinguish that the dose prescription can be done on a voxel level and could potentially lead to a more effective dose escalation rather than conventional treatment plans [9]. In particular, diffusion weighted imaging (DWI) can provide a quantitative measure of water diffusion through the apparent diffusion coefficient (ADC), a tissue biomarker directly derived by DWI [10]. Although the complex interactions between water and tissue microstructures were not been completely understood yet, in vitro and in animal models [11], [12], [13], [14] showed an inverse proportionality between cellular density and the ADC values. More recently, this relation has also been confirmed in patient studies [15], [16], [17]. Starting from this evidence and considering that the cellular density is proportional to the number of clonogens, ADC value can be considered a surrogate of the cellularity and of the number of clonogens [18], [19] in brain tumors and the ADC maps could be used as a guide for dose redistribution so that the highest dose values would be delivered on volume with the lowest ADC values. [18].

In a previous in silico work [20], the feasibility of the hypofractionated DPBN [21], [22], [23], [24], [25] approach guided by ADC maps on GBM recurrences with a Helical Tomotherapy was studied, with promising results on the treatment feasibility.

Considering the promising results reported in [20], a phase I–2 study (GLIORAD, NCT04610229), which had as primary objective the evaluation of safety of GBM re-treatment using a dose painting process, was clinically conducted in our institution.

For this trial, the development of a workflow was required to permit an advanced integration of imaging biomarkers into the radiation treatment planning process.

This work aimed to study and report the application of the dose painting technique in a clinical setting, discussing and exploring the planning workflow, the delivery strategies, and the patient-specific QA related to this in-vivo prospective clinical trial.

Access through your organization

Check access to the full text by signing in through your organization.

Access through your organization

Section snippets

GLIORAD study design

The present study was approved by the Ethics Committee of the AUSL-IRCCS Reggio Emilia (approval number GLIORAD 15–18 approved on 16 September 2015, ClinicalTrials.gov – identifier: NCT04610229) and carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. In accordance with Italian legislation, written informed consent was obtained from all patients.

Twelve patients with relapsed GBM after standard surgery radiochemotherapy treatment were enrolled.

Patient and plan characteristics

A total of 12 patients were enrolled and treated in this study and for each patient the workflow described in Fig. 1 was followed. All patients were generated considering the specific characteristics of each patient and were judged as clinically acceptable and deliverable.

Median [range] of GTV volumes was 33.57 [7.00; 69.39]. The number of levels for target discretization had a median [range] value of 7 [4; 9]. In particular, the minimum level number corresponded to the minimum GTV ...

Discussion

The idea of dose painting radiotherapy treatments is to escalate the dose to tumor volumes based on functional image data characteristics. In contrast with conventional dose escalation, the DPBN approach provides a non-homogeneous solution in which the dose is voxel by voxel customized based on a specific quantitative biomarker.

In this study, the application of dose painting by numbers guided by the MRI-ADC map was studied on a clinical trial as described by recurrent GBM. In particular, we ...

Conclusions

A phase 1–2 study was conducted on the possibility of DPBN approach for recurrent GBM patients. In this work, the workflow that permits the necessary integration between imaging biomarkers and dose painting process was described. The proposed method is independent from the TPS and can be considered to any anatomical sites and imaging-related biomarker.

Plan quality, robustness and deliverability were reported and discussed, and the technical feasibility of voxel-based DPBN approach was ...

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the IRCCS-AUSL Reggio Emilia (approval number GLIORAD 15–18 approved on 16 September 2015, ClinicalTrials.gov – identifier number: NCT04610229) ...

Informed consent Statement

In accordance with Italian legislation, informed consent was obtained from all subjects involved in the study. ...

Funding

This study was partially supported by Italian Ministry of Health – Ricerca Corrente Annual Program 2026.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ...

References (41)

S.W. Lee et al.
Patterns of failure following High-Dose 3-D Conformal Radiotherapy for High-Grade Astrocytomas: a Quantitative Dosimetric Study
Int J Radiat Oncol Biol Phys (1999)

T.C. Schulteis et al.
Radiation Response of the Central nervous System
Int J Radiat Oncol Biol Phys (1995)

T. Veninga et al.
Reirradiation of Primary Brain Tumours: Survival, Clinical Response and Prog-nostic Factors
Radiother Oncol J Eur Soc Ther Radiol Oncol (2001)

V.K. Bentzen et al.
Molecular Imaging-based Dose Painting: a Novel Paradigm for Radiation Therapy Prescription
Semin Radiat Oncol (2012)

E.R. Gerstner et al.
Diffusion and Diffusion Tensor Imaging in Brain Cancer
Semin Radiat Oncol (2012)

G. Fan et al.
Usefulness of Diffusion/Perfusion-Weighted MRI in Rat Gli-oma: Correlation with Histopathology
Acad Radiol (2005)

M. Orlandi et al.
Feasibility of Voxel-based Dose Painting for Recurrent Glioblastoma Guided by ADC Values of Diffusion-Weighted MR Imaging
Phys Medica PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc ... (2016)
Biomed Phys AIFB

D. Thorwarth et al.
Hypoxia Dose Painting by Numbers: a Planning Study
Int J Radiat Oncol Biol Phys (2007)

G. Heijer et al.
Dose Painting by Contours versus Dose Painting by Numbers for Stage III Lung Cancer: Practical Implications of using a Broad or Sharp Brush
Radiother Oncol J Eur Soc Ther Radiol Oncol (2012)

T. Dirscherl et al.
Feasibility of TCP-Based Dose Painting by Numbers Applied to a Prostate Case with 18F-Choline PET Imaging
J Med Phys (2013)

M. Witte et al.
Dealing with Geometric Uncertainties in Dose Painting by Numbers: introducing the AIVH
Radiother Oncol (2011)

D. Rajasekaran et al.
A Study on the Correlation between Plan Complexity and Gamma Index Analysis in Patient specific Quality Assurance of Volumetric Modulated Arc Therapy
Rep Pract Oncol Radiother J Gd Cancer Cent Pozn Pol Soc Radiat (2015)
Oncol

R.K. Tsang et al.
Current Trends in the Surgical Management and Treatment of Adult Glioblastoma
Ann Transl Med (2014)

M. Ammirati et al.
Reoperation in the Treatment of Recurrent Intracranial Malignant Gliomas
Neurosurgery (1987)

P. Ciammella et al.
Safety of Isbenorgene Dose distribution IMRT for High-Grade Glio-ma Reirradiation: a prospective phase I/II Trial (GLIORAD TRIAL)
Cancers (2022)

D. Cavaro et al.
Toward Patient-specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma
PLoS One (2013)

A. Bright et al.
An Investigation of the Conformity, Feasibility, and Expected Clinical Bene-fits of Multiparametric MRI-Guided Dose Painting Radiotherapy in Glioblastoma
Neuro Oncol Adv (2021)

D. Schnoppel et al.
Diffu-sion-Weighted Echo-Planar magnetic Resonance Imaging for the Assessment of Tumor Cellularity in patients with Soft-Tissue Sarcomas
J Magn Reson Imaging JMRI (2009)

R. Zahraf et al.
Correlation of Diffu-sion-Weighted magnetic Resonance Data with Cellularity in Prostate Cancer
BJU Int (2008)

F. Matsumoto et al.
In Vitro Experimental Study of the Relationship between the Apparent Diffusion Coefficient and changes in Cellularity and Cell Morphology
Oncol Rep (2009)

There are more references available in the full text version of this article.

Cited by (0)

View full text

© 2026 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica e Sanitaria.

About ScienceDirect ▸ Remote access ▸ Contact and support ▸
Terms and conditions ▸ Privacy policy ▸ Cookie settings

All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

RELX

Feedback